MDT - Intra-Cellular Positive Data And Other News: The Good Bad And Ugly Of Biopharma
Intra-Cellular stock jumps as its bipolar trial delivers positive data
Intra-Cellular Therapies Inc. (ITCI) announced positive top-line data from its Phase 3 clinical trial of its lead drug candidate lumateperone. The trial was designed to evaluate the potential of lumateperone as an adjunctive therapy to lithium or valproate for treating major depressive episodes associated with Bipolar I or Bipolar II disorder.
The Study 402 met its primary endpoint with once daily lumateperone 42 mg dosage. The endpoint was related to improvement in depression as measured by change from baseline versus placebo on the MADRS total